Xarelto, with a generic name of Rivaroxaban, is one of the newest anticoagulants in the market today. It is classified as a blood thinner that helps prevent blood clots from obstructing the flow of blood to the vital organs. Unlike the old type of anticoagulants, Xarelto is prescribed in one uniform dose. It is an oral tablet and does not require laboratory testing and dietary adjustments.
First approved in 2011, Xarelto was designed to lessen the risk of blood clots resulting to deep vein thrombosis (DVT) or pulmonary embolism (PE) after a hip or knee replacement surgery. In November of that year, the FDA approved it for use in stroke patients for reducing the risks of stroke that has no relation to a valve defect. A year later, it also received fast-track approval for treating DVT or PE and to lower the risk of re-developing the conditions.
Manufactured by Bayer and marketed by Janssen Pharmaceuticals, Xarelto was the subject of a defective pharmaceutical product lawsuit recently. Users of the drug claimed that they were not warned about the risk of uncontrolled bleeding, one of the drug’s most dangerous side effects. For the first 8 months of 2013, Germany’s drug regulators received 968 reports of side effects resulting to 72 deaths. Likewise, there were 750 reports of adverse reactions, including 58 deaths. However, these reports dfo not prove that Xarelto was the cause.
According to the website of Williams Kherkher, companies are responsible for ensuring the safety of consumers by properly warning them of inherent dangers in their products. Most of the plaintiffs accuse Bayer of negliegence and failing to warn them of the side effects of Xarelto. Among the reasons they cited for the lawsuits include :
- Financial difficulties due to emergency visits, ongoing care, and lost wages
- Emotional distress from caring for relatives exepriencing medical problems
- Funeral expenses as a result of uncontrolled bleeding
- Bayer and Janssen Pharmaceutical’s liability for releasing a dangerous drug
One of the claimants was the family of a man who died after using Xarelto. The patient suffered from uncontrolled brain bleeding. He had only taken Xarelto for 10 days when the uncontrolled bleeding happened. To date, Bayer has received up to nine lawsuits concerning the use of the drug in the United States wince its approval in 2011. The case was filed in the District of Vermont on July 25, 2014.